At TheraPanacea, we aim at developing a holistic approach to unlock innovative AI powered solutions for personalized medicine.
Our best in class R&D department is continuously conducting research and partnering with the best experts to deliver cutting edge solutions.
We have proven go-to-market experience and regulatory expertise to propel a product from its R&D phase to achieving a class IIb product certification.

“In my year consulting for TPC I have found every interaction to be professional and pleasant — from CxOs to project managers to the excellent frontline neuroimaging and ML engineers! The neuroscience at TPC is top-shelf — rigorous, cutting edge, and collaborative. And I believe we are striking the right R&D balance between science and productisation in the Alzheimer’s space. I’ve felt more like a TPC team member than an external consultant. Long may it continue!”

Dr. Neil Oxtoby, PhD, UCL POND: Computational modeling of neurodegenerative disease progression; Data Science Lead, Deep Dementia Phenotyping (DEMON) Network.

Transforming Neuroscience Research and Neuroradiology with Artificial Intelligence

AI: A growing trend in supporting and improving R&D productivity by providing deeper insights.

Unlocking biomarkers discovery
Understanding brain disorders
Optimized RCTs
Pioneering personalized medicine

Therapanacea is attending CTAD 2023 – meet us in Boston!

“Evaluation of machine learning models that predict Alzheimer’s disease progression in observational studies and randomized clinical trials”
Sofia Broomé¹, Shibeshih Belachew², Bastien Caba², Enrica Cavedo¹, Jonathan Dubois², Audrey Gabelle², Refaat Gabr², Arie Gafson², Despoina Ioannidou¹ , Xiaotong Jiang², Yan Jin², Neil Oxtoby³, Menglan Pang², Nikos Paragios¹, Willem Huijbers²

¹TheraPanacea – Paris (France), ²Biogen – Cambridge (United States), ³Toybox Science – Mildenhall (United Kingdom)

Contact us